Agios Pharmaceuticals (AGIO) EPS (Weighted Average and Diluted) (2013 - 2026)
Agios Pharmaceuticals (AGIO) reported EPS (Weighted Average and Diluted) of -$1.69 for Q1 2026, down 9.03% on a YoY basis from -$1.86 in Q1 2025, and up 8.65% quarter-over-quarter from -$1.85 in Q4 2025.
Agios Pharmaceuticals (AGIO) EPS (Weighted Average and Diluted) (2013 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 11 years, with the latest figure at -$1.69 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 9.03% year-over-year to -$1.69; the trailing twelve-month figure through Mar 2026 stood at -$7.25 (down 164.5% YoY), and the FY2025 full-year result was -$7.12, down 161.17% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$1.69, up from -$1.85 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $16.22 in Q3 2024, with the low at -$1.93 in Q2 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.47 across 5 years, with a median of -$1.68 in 2022.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) plunged 356.72% — and 2024, when it soared 1089.02%.
- Agios Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.67 in 2022, then sank by 356.72% to -$1.72 in 2023, then dropped by 1.16% to -$1.74 in 2024, then retreated by 6.32% to -$1.85 in 2025, then advanced by 8.65% to -$1.69 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.69 (Q1 2026), -$1.85 (Q4 2025), and -$1.78 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn | -1.69 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.69 |
| Dec 31, 2025 | -1.85 |
| Sep 30, 2025 | -1.78 |
| Jun 30, 2025 | -1.93 |
| Mar 31, 2025 | -1.55 |
| Dec 31, 2024 | -1.74 |
| Sep 30, 2024 | 16.22 |
| Jun 30, 2024 | -1.69 |
| Mar 31, 2024 | -1.45 |
| Dec 31, 2023 | -1.72 |
| Sep 30, 2023 | -1.64 |
| Jun 30, 2023 | -1.51 |
| Mar 31, 2023 | -1.47 |
| Dec 31, 2022 | 0.67 |
| Sep 30, 2022 | -1.49 |
| Jun 30, 2022 | -1.68 |
| Mar 31, 2022 | -1.74 |
| Dec 31, 2021 | 0.07 |
| Sep 30, 2021 | -1.56 |
| Jun 30, 2021 | -1.36 |